RenovoRx, Inc. (RNXT)
RenovoRx, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
RenovoRx, Inc. (RNXT) is a Biotechnology company based in US with a market capitalization of $32.7M. Free cash flow was negative at -$11M. This page tracks RNXT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 10 employees · IPO Aug 26, 2021
Valuation
Valuation & price
$0.82as of May 17, 2026· -38.8% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
6.03
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$32.7M
Market cap
—
Revenue growth (YoY)
70.9%
Gross margin
-$11M
Free cash flow (USD)
-$6.9M
Net debt
Net cash position
49.7%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2019 → 2025
Free cash flow by year
2019 → 2025
Gross margin by year
2024 → 2025
Value screen
Graham defensive-investor tests
1
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 14, 2026 (EPS $-0.08)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 2, 2026Filing
Delisting Notice
- 8-K eventJun 30, 2026Filing
Equity Incentive Plan Amended
- Insider buyMay 21, 2026Filing
Insider Buy $20KVOLL MARK · Chief Financial Officer · $19.7K
- Annual reportMay 15, 2026Filing
10-K Filed
- 8-K eventMay 14, 2026Filing
Earnings Release
- Quarterly reportMay 14, 2026Filing
10-Q Filed
- FinancingApr 16, 2026Filing
Securities Registration
Questions
Frequently asked questions
What is RenovoRx, Inc.'s market cap?
RenovoRx, Inc. (RNXT) has a market capitalization of $32.7M.
What is RNXT's P/E ratio?
A meaningful P/E ratio is not available for RNXT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is RNXT's price-to-book (P/B) ratio?
RNXT trades at 6.03 times book value per share.
When did RenovoRx, Inc. last report earnings?
RNXT last reported earnings on May 14, 2026; the next date is not yet scheduled.
Are insiders buying RNXT stock?
Yes — SEC Form 4 filings show 1 open-market insider buy and 0 sells at RenovoRx, Inc. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.